Ascletis Pharma Inc.

Investors

Financials & Filing

2025

2024

2023

2022

2021

2020

2019

2018

Voluntary Announcement - Ascletis Announces Dosing of the First Patient in the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure
2022-09-28
Notification Letter with Request Form to Non-Registered Holders of Shares - Notice of Publication of Interim Report 2022
2022-09-27
Interim Report 2022
2022-09-27
Voluntary Announcement - Business Update
2022-09-16
Voluntary Announcement - Shanghai Public Health Clinical Center Completed Patient Enrollment in Clinical Study of PD-L1 Antibody ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection
2022-09-15
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2022
2022-09-02
Clarification Announcement - In Relation to the Change of Company Secretary and Authorised Representatives
2022-08-24
Change of Company Secretary and Authorised Representatives
2022-08-22
2022 Interim Results
2022-08-22
Voluntary Announcement - Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA
2022-08-22

3

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1